• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Biopharma M&A and Deal Making: Understanding the Latest Trends to Optimize Future Strategy Product Image

Biopharma M&A and Deal Making: Understanding the Latest Trends to Optimize Future Strategy

  • ID: 2517284
  • March 2013
  • Region: Global
  • 55 Pages
  • CBR Pharma Insights

The leading pharmaceutical players continue to face the combined threats of a difficult operating environment and patent losses while struggling to deliver on pipeline potential. Externalization strategies are a key means to boost future revenues and, indeed more imminently, to satisfy shareholder demands. However, the increasing size of the leading biopharmaceutical companies is necessitating their involvement in growing the numbers and size of deals year by year. This in itself, along with the rising financial firepower of the mid-tier players, has increased the level of competition for the most attractive targets.

Increased competition in the marketplace for M&A and licensing deals can artificially inflate the cost of these deals, distorting the balance of value, risk and return. As a result companies must employ more rigorous selection processes and expand search criteria to consider more diverse options if they are to maximize their returns on investment.

The report, “Biopharma M&A and Deal Making”, was written to support team and corporate strategic initiatives around the options that exist to grow revenues through externalization, whether by READ MORE >

Executive Summary

Chapter 1: Introduction
- What is driving the increased use of externalization in biopharma industry strategies
- Externalization strategies: the options
- Benefits of different deal types from M&A to arm’s length licensing

Chapter 2: Trends in recent deal activity
- M&A deal trends
- Key acquisitions in 2012 and the motives behind them
- Most acquisitive companies
- Licensing deal trends (Type of deal, Therapy area, Phase)
- Divesting - the other extreme
- Focus on: Deal activity in the generics sector

Chapter 3: Successful deal making
- Key steps to successful deal making
- Shift to earlier stage deals
- Differentiating capabilities to position company as "partner of choice“
- Focus on: Joint ventures in emerging markets

Chapter 4: Future deal activity
- Key companies to watch in 2013

Appendix

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos